Project Number 1R01AG051596-01A1 Agency/Funding Organization NIA Funding Year 2016 View Full Project Details for A DOUBLE-BLINDED, RANDOMIZED, CONTROLLED PHASE 2A SAFETY, PROOF-OF-CONCEPT AND EXPLORATORY END POINT TRIAL OF THE DRUG LM11A-31 IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE. Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 7. Early-stage Clinical Drug Development (Phase I and II Clinical Trials) l. Growth Factors and Hormones Researcher and Organization Principal Investigator WINDISCH, MANFRED Principal Investigator First Name MANFRED Principal Investigator Last Name WINDISCH Awardee Organization PHARMATROPHIX, INC. Awardee State California Contact PI Country United States Project Detail Funding Opportunity Announcement PAR-16-365: Pilot Clinical Trials for the Spectrum of Alzheimers Disease and Age-related Cognitive Decline (R01) FY Overall Cost $1,499,874 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official RYAN, LAURIE M Related Resources Clinical Trial Study of LM11A-31-BHS in Mild-moderate AD Patients
